Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have discovered a molecular mechanism that connects breast tissue stiffness to tumor metastasis and poor prognosis. The study may inspire new approaches to predicting patient outcomes and halting tumor metastasis.
Agendia co-founder and Chief Research Officer, Laura van't Veer, Ph.D., has won the European Inventor Award in the SME category. The European Inventor Award is a prestigious innovation award presented by the European Patent Office, with only 15 inventors nominated in a total of five categories worldwide.
“I am very concerned about the impact that Angelina Jolie has on the media,” Walter Rocca, professor of epidemiology and neurology at the Mayo Clinic in Rochester, Minnesota, stated. He wasn’t hinting to Jolie’s acting choices or waifish silhouette, but to the confusion surrounding her decision to remove her ovaries to prevent ovarian cancer. By Mélisande Rouger
Each year, approximately 1.6 million women in the USA have breast biopsies to diagnose or rule out cancer. Pathological diagnosis is considered the gold standard – how accurate are these diagnoses? Report: Cynthia E. Keen
Australian researchers have found that so-called 'triple-negative breast cancers' are two distinct diseases that likely originate from different cell types. This helps explain why survival prospects for women with the diagnosis tend to be either very good or very bad.
Cells have two different programs to safeguard them from getting out of control and developing cancer. One of them is senescence (biological aging). It puts cancer cells into a permanent sleep so they no longer divide and grow in an uncontrolled way. Now the research group led by Professor Walter Birchmeier (Max Delbrück Center for Molecular Medicine, MDC, Berlin-Buch) has discovered that an…
The Koning Breast CT (KBCT) system, which has been granted FDA approval, provides 3D breast of the entire breast from any orientation for diagnoses.
SOFIA is the new automated breast tomography system developed by iVu Imaging and presented at ECR 2015 by Hitachi. The system, beyond its charming name, offers some very charming features indeed which may make SOFIA the most comfortable scanner currently available on the market.
MRI is increasingly relevant to cancer management, especially to detect breast carcinoma. Professor Christiane K Kuhl from the department of diagnostic and interventional radiology at the University of Aachen, Germany, strongly advocated in favour of MRI in breast cancer screening during a dedicated Satellite Symposium organised by Bracco at ECR 2015. Report: Mélisande Rouger
It is tough enough to be a clinician reading dozens of mammograms every day to detect early signs of breast cancer. Now those same radiologists must become statisticians in order to decrypt dozens of studies, challenging whether it is worth reading mammograms in the first place. Report: John Brosky
In breast cancer care each patient receives personalised, highly effective diagnosis and treatment procedures. In breast diagnostics this mainly revolves around new MRI scanning procedures that allow the quantification of biological and physiological processes on a cellular and molecular level.
A magnetic resonance spectroscopy (MRS) technique that monitors biochemical changes in tissue could improve the management of women at risk of breast cancer.
At the recent North American IHE Connectathon in Cleveland, Sectra (STO: SECT B) successfully completed testing of the IHE profiles MAMMO and DBT (Digital Breast Tomosynthesis). The testing was done using Sectra PACS which implements the Image Display and Image Manager actors of these profiles.
Carestream will show enhancements to its digital breast tomosynthesis (DBT) module including a slabbing tool, improved workflow capabilities and the display of DICOM-compliant 2D synthetic views (which are generated from the 3D dataset) at the 2015 European Conference of Radiology. The latest DBT module is currently available.
Women with metastatic breast cancer know they have a slim chance of long-term survival. The question is whether personalised therapy could extend their lives. Report: Cynthia E Keen
A panel of experts has recommended that existing programmes be phased out and that systematic screening programmes be replaced with systematic screening information that would give women the opportunity to make individual choices. Report: Mark Nicholls
A new study has suggested that mammography screening of healthy women can help to significantly reduce deaths from breast cancer. Much will now depend on new treatments and more systematic management of patients. Report: Mark Nicholls
Expert estimates suggest that women eating more poultry, fish, nuts and legumes and less red meat might have lower risk.
Created by the Dutch industrialist family Hilekes, in 1993 Medicor expanded beyond the Benelux countries to enter the German-speaking world as Medicor Germany GmbH, selling contrast media injectors for CT, MRI and angiography.
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.
Why is early detection of breast cancer so important? Professor Dr Walter Heindel, Director of the Institute of Clinical Radiology at University Hospital Münster, Germany, offers an unequivocal answer.
Breast cancer hurt her but after a long treatment, she is now 10 years past the day she heard "You have cancer."
It may well be the first computer-aided detection (CAD) software that went to school with radiologists to study breast cancer.
In May, 2013, the U.S. Food and Drug Administration (FDA) finally took the training wheels off tomosynthesis by approving the use of Hologic's new C-View 2D imaging in place of conventional 2D mammograms previously required as part of a breast tomosynthesis screening exam.
RSNA opens a window for one week where companies can showcase the latest technologies ahead of regulatory approval. Fujifilm seized this opportunity to introduce the leading edge in tomosynthesis, the Amulet Innovality that it has launched in Europe, and that once given the green light by the FDA will come to America under the name Aspire Cristalle.